课题基金 / 基金详情

CORE--GERIATRIC CLINICAL PSYCHOPHARMACOLOGY

CORE--GERIATRIC CLINICAL PSYCHOPHARMACOLOGY
核心--老年临床精神药理学
批准号:
6273528
负责人:
BRUCE G POLLOCK
金额:
$23.24万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-04-15 至 1999-02-28

项目摘要

项目成果

BRUCE G POLLOCK的其他基金

相似基金

相关文献

中文摘要
翻译
这一核心侧重于抗抑郁药物的研究,并特别关注 去甲替林和帕罗西汀对血小板5-羟色胺再摄取的影响 被抗抑郁药物的使用打断了,包括双重- 新型5-羟色胺再摄取抑制剂帕罗西汀的盲法研究 与更广泛使用的去甲替林相比。该研究的目标是 记录老年人的药代动力学变化。一个主要目标是 目前的核心是为其他核心和相关的 研究人员的项目侧重于药代动力学/药效学 评估,并为学生和地区提供相关指导 养老院,体内(表型)和体外(药物代谢分析) 新陈代谢酶细胞色素P450功能的研究 重要的抗抑郁药。
英文摘要
This Core focuses on antidepressant studies and is particularly concerned with the assay of nortriptyline and paroxetine platelet 5-HT reuptake interrupted by the use of antidepressant medication, including a double- blind study of paroxetine, a potent innovative serotonin reuptake inhibitor versus the more generally used nortriptyline. The goal of the study is to document pharmacokinetic changes in elderly adults. one primary goal of the present Core is to provide support for other cores and relevant projects of the investigators focused on pharmacokinetic/pharmacodynamic assessments, and to provide relevant instruction for students and area nursing homes, in vivo (phenotyping) and in vitro (drug metabolic assays) studies of cytochrome P450 function, an enzyme responsible for metabolism of significant antidepressants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CONTINUATION PHARMACOTHERAPY FOR AGITATION OF DEMENTIA
Continuation Pharmacotherapy for Agitation of Dementia
Geropsychopharmacology: Enhancing Benefit, Reducing Risk
Geropsychopharmacology: Enhancing Benefit, Reducing Risk
海外基金